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Inflow thrombosis does not adversely affect
thrombolysis outcomes of symptomatic iliofemoral
deep vein thrombosis
Geetha Jeyabalan, MD, Luke Marone, MD, Robert Rhee, MD, Stanley Hirsch, MD,
Michel S. Makaroun, MD, JaeSung Cho, MD, and Rabih A. Chaer, MD, Pittsburgh, Pa
Objective: The presence of popliteal or tibial vein clot is thought to adversely affect thrombolysis for iliofemoral deep vein
thrombosis (DVT). We examined the effect of inflow thrombosis on functional and anatomic outcomes.
Methods: Data for 44 patients treated for symptomatic iliofemoral DVT between 2006 and 2009 were retrospectively
reviewed. All patients were treated by pharmacomechanical thrombectomywith local lytic therapy. Catheter-directed lysis
and vena cava filters were used sparingly. Univariate and multivariate logistic regression analyses were used. The
independent variable used in the logistic regression model was symptom relief.
Results: Forty-four patients (mean age, 52.1  15.8 years) presented with symptoms averaging 13.4  9.9 days in
duration. Twenty (45.4%) had symptoms for >14 days. Seventeen patients were treated in one session, but 27 patients
required lytic infusion for residual thrombus. Iliac stenting was required in 49% of limbs. Successful lysis (>50%) was
achieved in 91% of patients, and symptom resolution or improvement in 91%. All patients became ambulatory, with no
or minimal limitation. No major systemic bleeding complications occurred. Freedom from DVT recurrence and
reintervention was 84% at 24 months by life-table analysis. Preoperative ultrasound imaging showed 89% had popliteal
and tibial clots. A thrombosed popliteal vein was accessed for treatment and was corroborated by venographic findings.
One patient required simultaneous tibial lysis. At a mean follow up of 8.7  6.3 months, 41 patients (93%) had no
symptom recurrence, 82% had preserved valve function and no reflux on duplex imaging, with a mean CEAP class of 1.4
and Villalta score of 3.3. Inflow thrombus had no adverse effect on symptom relief, treatment duration, patency, CEAP
class, or valve reflux. Interestingly, 90% of patients with initial popliteal thrombus had a patent popliteal vein on postlysis
ultrasound imaging, and the presence of tibial thrombus on presentation was predictive of symptom relief with
thrombolysis (odds ratio, 13.03; 95% confidence interval, 1.02-165.58; P  .048).
Conclusions: Inflow thrombosis is common and does not preclude successful thrombolysis of iliofemoral DVT. Valve
function is preserved on midterm follow-up, with maintained CEAP class and symptom relief. ( J Vasc Surg 2011;54:
448-53.)
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uAcute symptomatic iliofemoral deep vein thrombosis
(DVT) is associated with significant long-term post-
thrombotic morbidity if not treated aggressively and expe-
ditiously. Current guidelines based on the best evidence
suggest that thrombolysis for iliofemoral DVT to achieve
early thrombus removal can reduce acute symptoms and
long-term postthrombotic sequelae in select patients with
defined presentation, risks, and clot distribution.1
Unfortunately, patients with iliofemoral DVT will often
have concomitant involvement of the popliteal and tibial
veins.2,3 Inflow thrombosis has been traditionally handled
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448ith extra caution. Although the mainstream approach is to
uncture the ipsilateral uninvolved popliteal vein, several stud-
es specifically advocate clearing the popliteal/tibial vein
hrombus before initiating iliofemoral lytic therapy.4,5 Other
tudies of catheter-directed thrombolysis (CDT) or pharma-
omechanical thrombectomy (PMT) for iliofemoral DVT
ave gone to the extreme of often excluding patients with
oncurrent inflow thrombosis because it is thought to limit
pstream blood flow for effective delivery of the lytic agent.6
Furthermore, data from large randomized trials have
emonstrated lower patency rates after lysis of femoropopli-
eal DVT compared with iliofemoral DVT but did not exam-
ne populations with concurrent iliofemoral and popliteal
hrombosis.2 Current existing data are therefore insufficient
o clearly determine whether inflow thrombosis adversely
ffects outcomes after thrombolysis for acute iliofemoral or
emoropopliteal DVT. This study examined the effect of in-
ow thrombosis on functional and anatomic outcomes in
atients undergoing lytic therapy for acute iliofemoral DVT.
ETHODS
This study was approved by the Institutional Review
oard at the University of Pittsburgh. Individuals who
nderwent thrombolysis for symptomatic iliofemoral DVT
rom 2006 to 2009 were identified from a prospectively
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Volume 54, Number 2 Jeyabalan et al 449collected database. The records were retrospectively re-
viewed for demographics, indications for treatment, chro-
nicity of symptoms, contraindications for lysis, DVT loca-
tion based on duplex ultrasound (DUS) imaging, DVT risk
factors, adjunctive interventions, such as inferior vena cava
(IVC) filter placement, periprocedural complications, clin-
ical outcomes, and follow-up DUS imaging findings.
CEAP and Villalta scores were obtained at the follow-up
points of 3, 6, and 12 months.7-9
Medical therapy consisted of therapeutic anticoagula-
tion with heparin or equivalent periprocedurally, followed
by warfarin therapy of various durations determined by
underlying indication. Antiplatelet therapy with aspirin was
initiated in patients undergoing iliac vein stenting.10 Pa-
tients underwent a hypercoagulable hematologic workup,
if indicated, and follow-up with hematology specialists. All
patients with significant or extensive iliofemoral DVT had a
hematology consultant monitoring them through their
hospitalization. Decisions regarding duration of anticoag-
ulant therapy and whether a hypercoagulable work-up
should be initiated were made in conjunction with hema-
tologists. Graduated compression stockings were given to
all patients.
As described in previous studies published on this sub-
ject from our institution, all patients were severely symp-
tomatic despite therapeutic anticoagulation and usually
presented with a combination of pain, limb swelling, or
phlegmasia.11 Patients were administered intravenous hep-
arin preoperatively on a protocol to maintain therapeutic
partial thromboplastin times. All patients underwent color-
flow DUS imaging preoperatively in addition to computed
tomography of the chest, abdomen, and pelvis with intra-
venous contrast and a venous phase.
All interventions were performed by vascular surgeons
in endovascular suites equipped with fixed imaging capabil-
ity (GE Healthcare, Giles, United Kingdom). The degree
of residual thrombus was characterized as no lysis, 50%
lysis (partial), or 50% lysis on venography.2 Procedural
success was defined as 50% lysis according to reporting
standards; however, thrombolysis was performed with the
intent to achieve near-complete thrombus resolution.
Before discharge, duration of anticoagulant therapy
was determined by the vascular surgery and hematology
teams. This was determined by the underlying etiology of
the DVT and the presence or absence of a hypercoagulable
state. Premature discontinuation of anticoagulant therapy
was defined as any alteration from these guidelines. Patients
with underlying malignancy were prescribed lifelong anti-
coagulation with low-molecular-weight heparin or warfa-
rin, as determined by their hematologist/oncologist.
Thrombolysis technique. Caval interruption with
temporary IVC filters was performed selectively at the
beginning of the procedure, as described in previously
published data from our institution.11 Filter access was
performed via the jugular approach when patients were
prone when they underwent lysis. A 9F short sheath was left
in the jugular position throughout the duration of lysis to macilitate filter retrieval at the completion of the procedure
nd to minimize the risk of hematoma formation.
In the prone position, access was commonly obtained
o the middle-to-distal popliteal vein under US guidance.
ll patients were treated under conscious sedation and local
nesthesia. Imaging of the access site was routinely re-
eated at the start of the procedure by US imaging and
ompression as well as with venography. Heparin anticoag-
lation was routinely dosed at 100 U/kg. Ascending
enography was performed via a 6F or 8F sheath. The initial
ccess sheath was only partially introduced into the popli-
eal vein to allow visualization of the extent of clot distri-
ution. In patients with thrombosis at the access site, 2 mg
f tissue plasminogen activator (tPA, Alteplase, Genentech,
an Francisco, Calif) was routinely delivered through the
heath at the beginning of the procedure.
In patients with acute DVT, PMT was used with the
ntent of providing a single session treatment, if possible.
hen the AngioJet (Possis Medical, Minneapolis, Minn)
as used, the DVX catheter (Possis) was used in power-
ulse mode, initially with 6 to 8 mg of tPA per segment
reated. The catheter was then reactivated in thrombec-
omy mode after a 15-minute dwell time. Similar doses of
PA were used when the Trellis device (Bacchus Vascular,
anta Clara, Calif) was used for each 30-cm segment. As
escribed previously, patients with a thrombosed indwell-
ng IVC filter were treated with inflation of the Trellis
evice distal balloon above the filter for outflow control.
he choice of the AngioJet vs Trellis device was at the
iscretion of the operator. CDT was selectively used as
eeded for residual thrombus using a multiple sidehole
atheter or US-assisted CDT with the EKOS catheter
EKOS Corpor, Bothell, Wash).12,13 Iliac vein stenoses
een on completion venography were treated with self-
xpanding stents at the discretion of the operating surgeon.
Completion venography was routinely performed, and
esidual thrombus at the sheath access site that did not
ppear to limit the flow was tolerated and did not preclude
ermination of the procedure.
Statistical analysis. An independent statistician per-
ormed all advanced statistical analyses. The data have been
ummarized as mean  standard deviation for continuous
ariables and as percentages for categoric data. The inci-
ence of freedom from symptom recurrence was calculated
y life-table analysis. The time component started on the
ate of the initial procedure.
ESULTS
During the 2.6-year period, 44 patients with lower
xtremity DVT were treated with thrombolysis. The pa-
ients mean age was 52.1  15.8 years, and the average
ymptom duration was 13.4  9.9 days (Table I). Symp-
oms had lasted 14 days at the time of presentation in
5.4% of the patients. All patients were initially treated with
herapeutic anticoagulation but continued to experience
ersistent debilitating symptoms, including swelling, pain,
r limited ability to ambulate despite this therapy. Phleg-
asia was an indication for PMT in four patients.
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August 2011450 Jeyabalan et alAll patients underwent DUS imaging preoperatively,
nd studies were deemed adequate for evaluation of DVT
t the tibial and femoropopliteal levels. Preoperative color-
ow DUS imaging showed only 11% of patients had com-
lete absence of tibial vein involvement. Popliteal and tibial
ein thrombosis were both present in 39 of the 44 patients.
espite these findings, only one patient was treated with
imultaneous iliofemoral and tibial lysis.
Only one PMT session was required in 17 patients, but
7 patients required a combination of PMT and additional
ytic infusion because of residual thrombus seen on com-
letion venography. The duration of lytic infusion ranged
rom 14 to 36 hours. Successful lysis (as defined by 50%
ysis) was achieved in 91% of patients treated, resulting in
0% to 90% thrombus clearance on completion venogra-
hy. Iliac stenting was performed in 49% of limbs to correct
emodynamically significant iliac lesions. Intravascular US
maging was used only when venographic findings were
uestionable for the presence of iliac vein stenosis. The
able I. Continued
haracteristics
Percent (No.) or
Mean  SD
(Median, Range)
(n  44)
Left 68 (13/19)
Bilateral 21 (4/19)
ompleteness of lysis 91 (39)
50% lysis 5 (2)
50% lysis no lysis 5 (2)
erioperative complications
Minor access site bleed 5 (2)
Systemic bleed 9 (4)
Arrhythmia 5 (2)
Transfusion needed 9 (4)
Renal insufficiency 7 (3)
ymptom relief at last follow-up
None 0 (0)
Minimal 7 (3)
Moderate 33 (14)
Complete 61 (26)
mbulation status at last follow-up
Nonambulatory 0 (0)
Ambulatory/limited 33 (14)
Ambulatory/unlimited 68 (31)
ltrasound evidence at last follow-up
No evidence of DVT 45 (19)
Minor residual chronic changes 43 (18)
Recurrent 2 (1)
Persistent 10 (4)
No valve reflux 82 (31)
EAP class
No significant findings 57 (20)
Ankle edema 31 (11)
Skin pigmentation 9 (3)
Open ulcer 3 (1)
ean time in study (months) 8.7  6.3
reedom from DVT reintervention 95.4%
DT, Catheter-directed thrombectomy; DVT, deep vein thrombosis; GI,
astrointestinal; IVC, inferior vena cava; PMT, pharmacomechanical throm-
ectomy; PUD, peptic ulcer disease.Table I. Patient characteristics perioperatively
Characteristics
Percent (No.) or
Mean  SD
(Median, Range)
(n  44)
Mean age (years) 52.1  15.8 (54, 22-82)
Male 57 (25)
Indications (multiple allowed)
Swelling 23 (10)
Pain 75 (33)
Phlegmasia 16 (7)
Cauda equina 2 (1)
Risk factors (multiple allowed)
Cancer 16 (7)
History of DVT 23 (10)
Hypercoagulable state 34 (15)
Immobile 9 (4)
Recent surgery 14 (6)
Time from symptom onset to lysis
(days) 13  10 (12, 1-31)
Symptoms 14 days 45 (20)
Pulmonary embolism on presentation
None 82 (36)
Subclinical 7 (3)
Clinically significant 11 (5)
CEAP at pre-op
No findings 25 (2)
Ankle edema 50 (4)
Skin pigmentation 25 (2)
Hemostatic contraindications
Renal/liver failure 9 (4)
Recent (10 days) minor surgery 5 (2)
Major contraindications
PUD/GI bleed 2 (1)
Major surgery or trauma 16 (7)
Organ biopsy 5 (2)
Active bleeding 11 (5)
DVT site 9 (4)
Fempop 2 (1)
Iliac 5 (2)
Iliocaval 9 (4)
Iliofem 34 (15)
Fempop/iliac 36 (16)
All 3 (1)
All  tibial fempop & iliocaval 3 (1)
DVT tibial involvement 50 (22)
DVT popliteal involvement 89 (39)
Side
Right 20 (9)
Left 36 (16)
Bilateral 43 (19)
Approach
Popliteal 98 (43)
Femoral 0 (0)
Internal jugular 2 (1)
Basilic 0 (0)
Indwelling IVC filter (yes/no) 43 (19)
Thrombosed 84 (16 of 19)
PMT type
None 2 (1)
Trellis 30 (13)
Possis 33 (14)
Trellis/Possis 35 (15)
CDT 49 (21)
Overnight lysis 14 (6)
Stent implanted
Stent location 49 (19)reprocedural US scan showed tibial/popliteal clot in 39
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Volume 54, Number 2 Jeyabalan et al 451patients, and sheaths were placed in an ipsilateral throm-
bosed popliteal vein in 34.
There were no significant periprocedural bleeding
complications. At a mean follow-up of 8.7  6.3 months,
all patients were ambulatory, withminimal or no limitation.
Femoral and popliteal vein valve function was preserved in
82% of patients, and there was no evidence of reflux on
follow-up DUS imaging. Symptom resolution or improve-
ment occurred in 41 of 44 patients, and 37 remained free
from DVT recurrence and reintervention at 24 months by
life-table analysis (Fig). Recurrence occurred in patients
with malignancy, failure of anticoagulation (defined as
symptomatic DVT recurrence despite therapeutic warfa-
rin), or premature discontinuation of anticoagulation.
DVT recurred in four patients, but only two required
reintervention after the initial lysis. These two patients
underwent successful repeat lysis at 1 week and 6 months
and continue to be thrombus free, one patient recurred
with minimal symptoms and anticoagulation therapy was
continued, and the last patient had spontaneous recanali-
zation at last follow-up with no recurrent symptoms. The
patient who was relysed at 1 week was receiving subthera-
peutic anticoagulation and was erroneously bridged with a
prophylactic dose of low-molecular-weight heparin at dis-
charge. The patient whowas relysed at 6months decided to
discontinue her warfarin and had factor V Leiden defi-
ciency. In the other two patients, asymptomatic recurrence
of DVT was documented on surveillance DUS.
A logistic regression analysis was performed to identify
factors associated with symptom relief, the presence of
reflux on US imaging, unlimited ambulation, and risk of
DVT requiring reintervention. Dependent variables were
included in the model based on a cutoff value of P .25 on
univariate analysis. Factors that were associated with symp-
tom relief are listed in Table II.
The CEAP scoring system was used to assess patients
at follow-up.7 The mean CEAP score was 1.4. Post-
thrombotic syndrome (PTS) was also measured using an
additional assessment, the Villalta scale, a clinical assess-
ment of symptoms by the vascular surgeon looking at
symptom severity and signs of PTS.8,9 The mean Villalta
score in these patients was 3.3 at the last available follow-up
for individual patients. Freedom from symptom recurrence
remained high at 95.4% (42 of 44 patients), at 2-year
follow-up (Fig, A).
Although the preoperative US scans and procedural
venograms identified inflow thrombosis in nearly all pa-
tients, the postoperative US scan showed 35 patients (90%)
had a patent popliteal vein, even in previously thrombosed
segments.
DISCUSSION
The existing literature documents that the strategy of
thrombus removal often entails addressing inflow throm-
bosis to ensure effective upstream delivery of the lytic agent
as well as to ensure patency of calf and popliteal veins. This
strategy is inconsistent, however, and ranges from denial of
treatment to pedal lysis of inflow thrombosis. Along with the procedural guidelines in the Acute Venous Throm-
osis: Thrombus Removal With Adjunctive Catheter-
irected Thrombolysis (ATTRACT) protocol, we have
dopted a strategy of iliofemoral lysis regardless of the
hrombus in the popliteal/tibial veins.14
The standard protocol at our institution is to address
roximal iliofemoral and femoropopliteal DVT by access-
ng the ipsilateral involved popliteal vein with the patient
rone. Local instillation of tPA at the sheath insertion site at
ompletion of the PMT of the involved proximal segments
s routine, which might explain the patent inflow seen on
ollow-up DUS imaging despite initial thrombosis. To
oncomitantly treat even more distal tibial venous throm-
osis, the sheath would need to be turned caudad, or a
eparate more distal tibial venous access would have to be
btained. This adds both time and lytic agent exposure to
he procedure. Additional lytic agent is not inconsequential
n patients with a large clot burden proximally who are
lready at risk for hemorrhagic complications.
Some have suggested that inflow thrombosis limits
ffective delivery of lytic agent to more proximal segments.
urthermore, some studies have suggested that popliteal
eflux alone can lead to significant PTS morbidity.15-17 In
his study, we did not find any significant adverse functional
r anatomic outcomes when inflow lysis was not performed
eparately. Interestingly, patients in whom popliteal venous
hrombosis was documented on preoperative DUS had
atent popliteal veins on postoperative DUS after just local
reatment, as described above. Patients with recurrent DVT
r who required reintervention did not have a higher
ncidence of inflow thrombosis compared with patients
ho did not. These patients typically had specific risk
actors for DVT recurrence, such as underlying malignancy
r relative contraindications to prolonged lytic therapy (eg,
ecent operations).
We have recently demonstrated that these techniques
an be used successfully and safely and with good out-
omes, even in patients previously thought to be high risk
r to have relative contraindications to lysis.11 Patients
resenting with acute or subacute DVT and lower extrem-
ty swelling may be difficult to image by DUS techniques.
hey may be intolerant to compression, and the compart-
ent swelling and edema may limit the identification of
enous structures and the accurate diagnosis of DVT. Rec-
gnizing the limitations of DUS in the swollen tender
xtremity, we confirmed the diagnosis of inflow thrombosis
y intraprocedural DUS examination while the patient was
edated so that compression could be applied while mini-
izing patient discomfort. Paired tibial veins were also
ccasionally used as internal controls on color-flow DUS
maging to confirm tibial thrombosis when compression
as not possible. In addition, venography through the
ccess sheath was routinely performed while the sheath was
arely in the popliteal vein, which allowed the clear identi-
cation of inflow thrombosis and sometimes results in
imited dye refluxing into the infrageniculate segment of
he popliteal vein.
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to specifically examine the outcomes of patients with acute
symptomatic DVT undergoing conventional therapeutic
Fig. A, Freedom from deep vein thrombosis-related sym
from deep vein thrombosis-related symptoms recurr
postprocedure.anticoagulation vs catheter-directed lysis in addition to therapeutic anticoagulation. Clinical and physiologic end
oints will both be measured, and patients are stratified
ccording to the iliofemoral vs femoropopliteal location of
ms at specified time points postprocedure. B, Freedom
stratified by inflow status at specified time pointspto
encehe DVT. The presence of inflow thrombus (thrombosis in
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for enrollment. The ATTRACT trial does not specify
guidelines on how to address the presence of inflow throm-
bosis. Given that this is a multicenter trial and the treatment
of inflow thrombosis varies by institution, a subgroup anal-
ysis may be worthwhile to further determine whether long-
term outcomes are affected by the presence of inflow
thrombosis.
Our study is limited by its retrospective nature and
small patient number. However, even among patients with
DVT recurrence or who required reintervention, the inci-
dence of inflow thrombosis was not higher than in patients
who remained free of recurrence. Ultimately, the long-
term benefits of PMT and lysis are to restore luminal
patency and to preserve valve function. Given that attempts
are still being made to fully understand which patients may
benefit from invasive approaches to treat symptomatic
DVT, it is important to simultaneously delineate which
technical aspects of the procedure are necessary to accom-
plish these goals.
CONCLUSIONS
The presence of inflow thrombosis does not seem to
have any adverse effect on symptom relief, thrombus recur-
rence, and the development of PTS at early time points in
patients offered thrombolysis for iliofemoral DVT. Inflow
thrombosis is common and does not preclude successful
thrombolysis of iliofemoral DVT. Symptom relief is main-
tained, and valve function and vein patency are preserved at
midterm follow-up. Data from larger-scale studies are
needed to clearly identify the role of inflow treatment in
patients undergoing thrombolysis.
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